Literature DB >> 2185627

Mortality rates among dialysis patients in Medicare's End-Stage Renal Disease Program.

P W Eggers1.   

Abstract

Medicare's End-Stage Renal Disease (ESRD) Program provides funding for life-saving renal replacement therapy for patients with irreversible chronic renal failure. Although more than 100,000 patients are currently alive due to dialysis and transplantation, mortality among ESRD patients is still much higher than in the general population. Gross mortality, calculated from aggregate statistics such as those available from the annual ESRD facility survey, is an extremely imprecise measure of mortality and can lead to misleading conclusions. Standard methods of survival calculation such as actuarial life-table analyses provide more accurate descriptions of variations and trends in mortality. The most important characteristic influencing mortality among ESRD patients on dialysis is the changing age and diagnostic distribution. The average age of dialysis patients has increased by over 5 years during the past decade. Patients whose renal failure is attributed to diabetic nephropathy currently account for 30% of all patients initiating renal replacement therapy each year and constitute the fastest growing group of ESRD patients. From 1982 to 1987, 1-year survival on dialysis was 72.7% for patients whose renal failure was attributed to diabetic nephropathy and 79.8% for all other patients. Survival decreases rapidly with advancing age at time of renal failure, from 95.1% among patients 15 to 24 years to 52.5% for patients over the age of 85 (for non-diabetics). Survival rates for whites are 5% to 6% lower than for other racial categories. There are no obvious trends in mortality among dialysis patients over the past decade. For patients whose renal failure is attributed to diabetic nephropathy, survival rates have remained constant despite overall aging in this group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2185627     DOI: 10.1016/s0272-6386(12)70359-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Relationships of clinic size, geographic region, and race/ethnicity to the frequency of missed/shortened dialysis treatments.

Authors:  Chamberlain Obialo; Phillip G Zager; Orrin B Myers; William C Hunt
Journal:  J Nephrol       Date:  2014-01-21       Impact factor: 3.902

2.  Essential trace elements in humans. Serum arsenic concentrations in hemodialysis patients in comparison to healthy controls.

Authors:  D R Mayer; W Kosmus; H Pogglitsch; D Mayer; W Beyer
Journal:  Biol Trace Elem Res       Date:  1993-04       Impact factor: 3.738

3.  Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.

Authors:  Robert Provenzano; Steven Fishbane; Lynda Szczech; Robert Leong; Khalil G Saikali; Ming Zhong; Tyson T Lee; Mark T Houser; Lars Frison; John Houghton; Dustin J Little; Kin-Hung Peony Yu; Thomas B Neff
Journal:  Kidney Int Rep       Date:  2020-12-24

4.  Kidney transplant in diabetic patients: modalities, indications and results.

Authors:  Erika B Rangel; João R de Sá; Cláudio S Melaragno; Adriano M Gonzalez; Marcelo M Linhares; Alcides Salzedas; José O Medina-Pestana
Journal:  Diabetol Metab Syndr       Date:  2009-08-26       Impact factor: 3.320

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.